186 results about "Type Vaccine" patented technology

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.

The invention discloses an adjuvant and application thereof in vaccine preparation. The amino acid sequence of the adjuvant is shown as SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 23, 27, 31, 35 or 39. The immune protection effect of the nanoparticle vaccine can be improved by activating TLR2, and good vaccine adjuvant activity is shown in a common immunogen SD or new coronavirus RBD immunogen model. Furthermore, an assembly construction method of the self-adjuvant-nanoparticle vaccine is optimized, and the prepared self-adjuvant-nanoparticle vaccine has a remarkable effect of inducing the generation of an antibody in an animal body. The novel adjuvant provided by the invention can be widely applied to vaccine research and development, and meanwhile, the assembled nanoparticle self-adjuvant vaccine can also become a novel vaccine.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

Disclosed in the present invention are an HLA-A*11-targeted liver cancer mRNA vaccine, and a preparation method therefor and a use thereof. The mRNA vaccine of the present invention is an mRNA vaccine designed on the basis of the HLA-A*11:01 typing of a patient and having high-coverage and high-immunogenic tumor neoantigens, and is formed by transcribing DNA having a nucleotide sequence shown in SEQ ID NO: 32 to form an mRNA, and encapsulating the mRNA in lipid nanoparticles.

The invention discloses an mRNA (messenger ribonucleic acid) transcription skeleton vector and application thereof in preparation of a self-amplification type mRNA vaccine, and belongs to the technical field of veterinary biological products. According to the invention, alphavirus non-structural protein regions NSP2 and NSP3 of a self-amplification type mRNA skeleton are modified, a polyA tail is optimized, and a novel self-amplification type mRNA skeleton is constructed; the self-amplification type mRNA vaccine can improve the antigen expression efficiency, reduce the toxicity of non-structural protein to cells and improve the encapsulation efficiency and delivery efficiency by combining with the optimization of the components and proportion of a lipid nano delivery system, and meanwhile, the self-amplification type mRNA vaccine is wide in applicable pathogen antigen range and can be popularized to more animal epidemic diseases. The characteristics of high-efficiency expression, low-toxicity delivery and single-dose immunization are expected to renovate the immunization strategy of the existing animal vaccine, the epidemic prevention cost of the breeding industry is reduced, and the method has a wide industrial application prospect.

The invention relates to the technical field of animal vaccines, and discloses an animal recombinant castration vaccine and a preparation method and application thereof, the animal recombinant castration vaccine comprises an animal castration vaccine antigen and an adjuvant, and the content of the animal castration vaccine antigen in the vaccine is 0.5-1 mg / mL. A gel type vaccine is prepared by adopting an animal castration vaccine antigen with an amino acid sequence as shown in SEQ ID No.2-4, and testis growth and development of rats are obviously inhibited after the rats are immunized. The animal castration vaccine antigen is also used for preparing vaccines in three dosage forms, namely an emulsion type vaccine, an aluminum salt type vaccine and a gel type vaccine, after the three vaccines are used for immunizing rats, the anti-GnRH antibody titer in the rats is obviously increased, the testosterone concentration is reduced (Plt; 0.05), and the testis growth and development are inhibited. The three dosage forms of vaccines all have good immune castration effect, and can be applied to castration or estrus inhibition of pets and economic animals in the future.

The invention discloses an ultralow-viscosity water-in-oil vaccine adjuvant and a preparation method thereof, and the ultralow-viscosity water-in-oil vaccine adjuvant comprises the following components in percentage by weight: 73%-75% of oil for injection, 20%-23% of a compound emulsifier, 2%-7% of a stabilizer, 0.5%-1.5% of a chiral immunomodulator and 1%-2% of a temperature-responsive material, the preparation method comprises the following steps: heating oil for injection as an oil phase; adding the compound emulsifier, the stabilizer, the chiral immunomodulator and the temperature response type material into the oil phase, stirring until the materials are completely dissolved to form a uniform oil phase mixture, slowly adding the water phase into the oil phase mixture, performing high-speed shearing to form primary emulsion, homogenizing the primary emulsion, and performing freeze drying to obtain the chiral immunomodulator. And carrying out emulsion refining by adopting a micro-fluidic technology to obtain the ultralow-viscosity water-in-oil type vaccine adjuvant. The ultra-low viscosity and injection comfort are achieved, precise immunization is achieved for different pathogens, multiple immune pathways are activated at the same time, a wide and lasting protection effect is generated by training an immune mechanism, and the ultra-low viscosity and injection comfort have the intelligent drug release characteristic, excellent stability and broad-spectrum applicability.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an NDRV [sigma] C circular RNA vaccine and application thereof, and belongs to the technical field of vaccines.Duck hepatitis A virus type 1 (DHAV-1) UTR and T4 bacteriophage I type intron self-splicing cyclization systems are adopted to construct circular RNA (CirRNA-[sigma] C) for expressing NDRV [sigma] C protein, and a vaccine preparation is prepared through a chitosan-polyethyleneimine (CS-PEI) nano delivery system. The feasibility of a circular RNA vaccine system based on DHAV-1UTR in poultry vaccines is confirmed for the first time, the established nano delivery technology and circular RNA vaccine platform have the characteristics of high stability, good safety, strong immunogenicity and the like, and an important technical path is provided for development of novel vaccines of NDRV and other viral epidemic diseases.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention discloses an oil-in-water vaccine adjuvant, an emulsion as well as a preparation method and application of the oil-in-water vaccine adjuvant, and relates to the technical field of vaccine adjuvant preparation. The adjuvant obtained by the invention is still not layered after being subjected to high-temperature and high-pressure moist heat sterilization. The contamination risk when the adjuvant is uniformly mixed after being subjected to high-temperature and high-pressure damp-heat degerming and layering is reduced, and vaccine manufacturers can conveniently carry out next-step production. The antigen and the adjuvant are mixed, and the prepared vaccine has higher immune efficacy than similar oil-in-water adjuvant vaccines. The oil-in-water adjuvant provided by the invention has good vaccine production and application prospects. When a vaccine composition is prepared on the basis of the oil-in-water vaccine adjuvant, high kinetic energy, high shearing, high-speed stirring emulsification and high-pressure homogeneous emulsification are not needed either, the emulsification process is greatly simplified, emulsification can be successful through low kinetic energy stirring, and vaccine production and use are more convenient and efficient.

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6 / 7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6 / 7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6 / 7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The invention relates to a method for detecting the in vitro relative potency of a type 9 HPV vaccine or antigen stock solution. Specifically, the in vitro relative potency of an HPV-VLP antigen stock solution and vaccine finished products (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) is detected by using an enzyme-linked immunosorbent assay. The enzyme-linked immunosorbent assay has excellent accuracy and precision, the standardization level of HPV vaccine quality evaluation is improved, and a foundation is expected to be laid for promoting research and development of high-quality HPV vaccines.

The present invention relates to a novel vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). According to the invention, after the SFTSV vaccine is injected in vivo, the formation speed of Gn and Gc proteins can be obviously accelerated. Besides, the vaccine can effectively stimulate humoral immune response, for example, a specific neutralizing antibody aiming at a virus antigen is induced to generate, so that a remarkable protection effect aiming at SFTSV is provided for an individual.

The invention discloses an antigen LARP1 of cysticercus bovis and application of the antigen LARP1, and belongs to the technical field of biochemistry. The invention aims to provide a detection method and a treatment and prevention method for cysticercosis bovis. The invention provides an antigen of cysticercus bovis. The amino acid sequence of the antigen of cysticercus bovis is as shown in SEQ ID NO. 4. And a new candidate antigen is provided for research and development of novel vaccines, development of specific diagnostic reagents and the like.

The invention provides a herpes simplex virus mRNA vaccine as well as a preparation method and application thereof. According to the present invention, through a series of selection and optimization, the antigen protein suitable for preparing the mRNA vaccine, especially the combination of gD2 and gE1, is obtained, and the divalent vaccine prepared based on the antigen protein has excellent effect. The novel mRNA vaccine disclosed by the invention can efficiently induce humoral immune response, cellular immune response and T cell immune response, so that the novel mRNA vaccine can be effectively used for preventing and controlling herpes simplex virus infection, and can simultaneously cover the prevention and control of two viruses, namely HSV-1 and HSV-2.

The invention relates to a nano polypeptide vaccine for preventing colorectal cancer and a preparation method thereof, the vaccine comprises an antigen, and the antigen contains a first polypeptide fragment and a second polypeptide fragment; the amino acid sequence of the first polypeptide fragment is VVGAVGVGK; and the amino acid sequence of the second polypeptide fragment is TPQDSRQVL. The invention provides a novel vaccine entrapped with the colorectal cancer specific antigen peptide, provides a new thought for preventing colorectal cancer, and has a wide prospect. The new antigen polypeptide is selected as a tumor antigen, and the peptide vaccine has the advantages that the peptide vaccine can target multiple tumor-related antigens, the sequence is clear, the good modification potential is achieved, operability is high, preparation and quality control are easy, and the economic cost is relatively low. The vaccine disclosed by the invention is good in safety, has an obvious prevention effect on colorectum, and can be used for obviously prolonging the life cycle of mice, inhibiting tumor growth, improving the anti-tumor immune response of colorectal cancer and inhibiting tumor cell proliferation.

This invention belongs to the field of biotechnology and relates to a specific monoclonal antibody against porcine circovirus type 2 (PCV2) Cap protein and its applications. The CDR of the heavy chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, respectively; the CDR of the light chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6, respectively. A sandwich ELISA method for protein content determination has been established, which is simple to operate, has good sensitivity and specificity, is widely applicable, and can perform high-throughput determination of multiple samples to detect the content of Cap protein, an effective antigen of various types of PCV2 vaccines, thus shortening the vaccine testing time.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The application discloses a temperature-uniform vaccine rewarming device, which belongs to the technical field of vaccine rewarming devices. The device comprises a shell, an electric heating wire arranged in the shell, a sealing cover threadedly connected to the upper side of the shell, a support disc sealingly and slidably connected to the shell, a water bath cavity formed by the shell and the support disc, water bath liquid stored in the water bath cavity, a support ring annularly arranged on the support disc, symmetrical connecting rods fixed to the lower side of the support ring, and an extrusion disc jointly and limitingly connected to the connecting rods symmetrically arranged on the same support ring. The connecting rod on one side is sealingly and slidably connected to a first extrusion cylinder fixed to the adjacent extrusion disc, and an annular air bag is fixed to the support ring. The annular air bag is inflated to separate the water bath liquid from the bottleneck of the vaccine, so that the water bath liquid is prevented from splashing into the bottle mouth of the vaccine during movement, and the probability of the vaccine being contaminated is reduced.

The invention provides preparation of a novel mRNA vaccine and application of the novel mRNA vaccine in a medicine composition for treating hepatitis B virus diseases. Specifically, the invention provides a chronic hepatitis B infection therapeutic mRNA vaccine, which comprises mRNA for coding a large protein (L protein) region of hepatitis B virus surface antigen, and simultaneously comprises two mRNA for respectively coding a middle protein (M protein) region of hepatitis B virus surface antigen and a small protein (S protein) region, or comprises mRNA for coding the small protein (S protein) region. The mRNA therapeutic vaccine provided by the invention can break the immune tolerance state in chronic hepatitis B infection, and has the potential of functionally curing chronic hepatitis B infection clinically.

The present invention discloses a method for preparing a metal organic framework-based Pickering emulsion vaccine and its application, comprising the following steps: using Al(NO3)3·9H2O and 4,4'-diphenyldicarboxylic acid as raw materials, obtaining white DUT-5 powder by a solvothermal method; adding the prepared DUT-5 to ultrapure water, and mixing by simple ultrasound to obtain a Pickering emulsion; mixing the obtained Pickering emulsion with PCV2Cap protein and placing it in a shaking table overnight; ultrafiltration and centrifugation of the obtained mixed emulsion to obtain DUT-5-PE@CAP. The vaccine of the present invention can effectively deliver antibodies or proteins to specific locations and stimulate a strong immune response, providing new possibilities for the development of new vaccines, and providing a new method for the prevention and treatment of porcine circovirus type II, which is of great significance for controlling the disease.

The invention discloses a pre-fusion RSV F protein mutant and application thereof. The invention provides a new RSV F protein mutation site, it is found for the first time that 157C and 183C substitution and / or 170C and 177C substitution in the respiratory syncytial virus F protein has an important effect on stabilizing conformation before fusion, S155C and S290C substitution can be not used, the immunogenicity of the respiratory syncytial virus F protein before fusion is improved, the neutralizing antibody titer induced by the respiratory syncytial virus F protein is greatly improved, and the immunogenicity of the respiratory syncytial virus F protein before fusion is improved. Meanwhile, the high expression level of the antigen in mammalian cells is achieved, and the method is used for preparing RSV diagnostic reagents, antibodies and various vaccines with the pre-fusion F protein as the antigen.

The invention discloses an anti-swine SLFN11 protein monoclonal antibody and application thereof, and relates to the technical field of biology. The anti-swine SLFN11 protein monoclonal antibody comprises a heavy chain variable region of which the amino acid sequence is shown as SEQ ID NO.1 and a light chain variable region of which the amino acid sequence is shown as SEQ ID NO.3. The invention further discloses a preparation method of the anti-swine SLFN11 protein monoclonal antibody. A heavy chain constant region of the monoclonal antibody is of an IgG1 type, a light chain constant region of the monoclonal antibody is of a Kappa type, and the monoclonal antibody has high affinity and stability and can be specifically combined with swine SLFN11 protein. The invention provides a good immunological tool for further exploring the antiviral function and mechanism of the SLFN11 protein, and lays a foundation for developing genetically engineered antibody drugs and novel vaccines for preventing or treating porcine viral diseases.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.